Trial Profile
Remission Induction by Etanercept in Enthesitis related Arthritis JIA-Patients (juvenile undifferentiated Spondylarthropathy) Remissionsstudie mit Etanercept bei Kindern mit Enthesitis-assoziierter Arthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Jan 2017
Price :
$35
*
At a glance
- Drugs Etanercept (Primary)
- Indications Juvenile rheumatoid arthritis; Spondylarthritis
- Focus Therapeutic Use
- Acronyms REMINDER
- 07 Dec 2015 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
- 23 Jun 2011 New trial record